Drugs / Recombinant Fowlpox-GM-CSF
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00096551 | Nov 2004 → Dec 2009 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00060528 | May 2003 → Mar 2006 | prostate neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00081848 Background | Apr 2004 → Aug 2007 | liver and intrahepatic bile duct neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Fowlpox-GM-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00081848 ↗ |
| Known as | rF-GM-CSF | “a fowlpox virus injected with DNA for GM-CSF, a chemical that boosts the immune system, called rF-GM-CSF.” NCT00081848 ↗ |
| Modality | Vaccine | “intratumoral vaccines of recombinant fowlpox vectors appear to be more potent in inducing antitumor effects” NCT00096551 ↗ |
| Route | Subcutaneous | “Given subcutaneously (s.c.) at site of vaccine” NCT00060528 ↗ |